ArticleJournal of the National Cancer Institute2025
Prostate cancer clinicopathological presentation in South-East Africa during the 2010 decade.
Article in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Africa's emerging role in precision oncology: translational insights from the harnessing functional genomics in cancer research conference, Windhoek, 23-26 September 2025.BMC proceedings · 2026Article
- Epigenetic modulation of prostate cancer disparities in men with African ancestry.Nature reviews. Urology · 2026Review
- Single base focal hypermutation cooccurs with structural variation as an early event in advanced prostate tumourigenesis with ancestry specific independence: a multi-ancestral observational study.Genome medicine · 2026Observational
- A unique transcriptomic landscape defines African-specific grade group 1 prostate cancer.Research square · 2026Article
- Single base focal hypermutation cooccurs with structural variation as an early event in advanced prostate tumourigenesis with ancestry specific independence: a multi-ancestral observational study.Research square · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Prostate cancer is the leading cause of cancer-associated death among men across Sub-Saharan Africa, with Southern and East Africa ranking first and fifth globally. However, lack of coordinated national cancer registries has biased data toward single-sourced, averaged, or model estimates. Here, our retrospective study included 8634 South-East African patients diagnosed between 2010 and 2019, which when compared with 71 694 Black and 322 356 White period-matched American men, were over threefold more likely to present with aggressive disease (International Society of Urological Pathology grade groups ≥4: 45.38% vs 21.22% and 21.05%; prostate-specific antigen ≥20 ng/mL: 62.04% vs 17.29% and 11.17%, respectively; all 2-sided P < .0001). East over Southern African men are 1.5 times more likely to present with advanced disease, however, age was not a confounder. Supporting prostate cancer as a major health concern for Africa, our data suggest underestimation in East Africa, while highlighting the need for accurate monitoring, increased awareness, and tailored screening criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.